Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by E. Echarri
Pmh40 - Cost-Minimisation Analysis of Second Generation Long Acting Injectables (Risperidone , Paliperidone, and Aripiprazole) for Schizophrenia in Spanish Medium-Long Term Care Psychiatric Units
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Treatment Cost Comparison: Paliperidone Palmitate Versus Risperidone Long Acting in Brazil
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost Effectiveness of Paliperidone Palmitate Versus Risperidone Long-Acting Injectable, Quetiapine and Olanzapine for the Treatment of Patients With Schizophrenia in Colombia
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Quality of Life of Patients Suffering From Schizophrenia and Treated With Long-Acting Risperidone and Paliperidone-Palmitate
Racionalna terapija
Caregiver Burden in Schizophrenia Following Paliperidone Palmitate Long Acting Injectables Treatment: Pooled Analysis of Two Double-Blind Randomized Phase Three Studies
npj Schizophrenia
Psychiatry
Mental Health
Cost/Effectiveness of Aripiprazole vs. Olanzapine in the Long-Term Treatment of Schizophrenia
Srpski Arhiv Za Celokupno Lekarstvo
Medicine
Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia
Psychiatric Services
Medicine
Psychiatry
Mental Health
Corrigendum to “Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia”
Case Reports in Psychiatry
Psychiatry
Mental Health
Pmh25 - Early Administration of Aripiprazole Long-Acting Injectable in Acute Inpatients With Schizophrenia Reduces the Cost of Hospitalization
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Treatment Discontinuation of Long-Acting Injectables or Oral Atypical Antipsychotics Among Medicaid Recipients With Schizophrenia
Journal of Medical Economics
Health Policy
